M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients

Table 2 Plasma levels of M-CSF, CA 125 and HE4 in tested groups

	Groups		M-CSF	HE4	CA 125
	Groups		(pg/ml)	(pmol/L)	(U/ml)
Ovarian cancer Median Range	stage I		¹	^1/2	¹
			444.40	83.54	63.62
			159.80 -2702.20	27.50-1093.80	12.50-650.4 0
	stage II		^1/2	^1/2	^1/2
			619.76	62.64	61.62
			221.70-1764.00	24.00-625.10	8.40-998.00
	stage III		^1/2/4	^1/2/4	^1/2/4
			706.45	117.92	766.84
			200.05-3791.05	47.00-1500.00	9.84-2060.78
	stage IV		^1/2/4	^1/2/4	^1/2/4
			1009.40	198.14	531.92
			235.64-2091.75	36.40-1944.20	13.64-8602.30
	Total group		^1/2	^1/2	^1/2
			633.00	103.64	133.39
			159.80-3791.05	24.00-1944.20	8.40-8602.30
	*Serous epithelial*		^1/5/6/7	^1/5/6/7	^1/5/6/7
			794.05	126.24	171.24
			221.7-3791.05	28.60-1944.20	8.40-8602.30
	*Endometrioid epithelial*		^1/6	^1/6/7	^1/6/7
			606.48	68.50	114.24
			159.80-3396.20	24.00-1740.00	10.92-1425.00
Control groups Median Range	Benign ovarian tumor	*Cystis endometrioides*	³	³	^3/8
			434.28	23.18	43.44
			125.30-2209.30	14.00-68.60	7.50-2748.00
		*Cystis serous*	³	⁸	³
			468.35	43.34	20.69
			166.90-1604.40	25.40-159.94	5.40-451.80
		Total group	³		³
			448.10	42.60	27.74
			125.30-2209.30	14.00-159.94	5.40-2748.00
	Healthy subjects		298.55	44.32	10.02
	Healthy subjects		119.63-1097.00	6.20-122.30	5.06-36.60

¹statistically significant when comparing EOC patients with healthy subjects.
²statistically significant when comparing EOC patients with benign ovarian tumor total group.
³statistically significant when comparing patients with benign ovarian tumor and healthy subjects.
⁴statistically significant when comparing EOC patients in stage III or IV with stage I or II.
⁵statistically significant when comparing EOC patients i.e. sub-type serous with sub-type endometrioid.
⁶statistically significant when comparing with benign ovarian tumor group i.e. type cystis endometrioides.
⁷statistically significant when comparing with benign ovarian tumor group i.e. type cystis serous.
⁸statistically significant when comparing patients with benign ovarian tumor i.e. type cystis endometrioides with type cystis serous.

ISSN: 1757-2215